Engineered Strategies to Interfere with Macrophage Fate in Myocardial Infarction
Source abstract
Abstract
Myocardial infarction (MI), a severe cardiovascular condition, is typically triggered by coronary artery disease, resulting in ischemic damage and the subsequent necrosis of the myocardium. Macrophages, known for their remarkable plasticity, are capable of exhibiting a range of phenotypes and functions as they react to diverse stimuli within their local microenvironment. In recent years, there has been an increasing number of studies on the regulation of macrophage behavior based on tissue engineering strategies, and its regulatory mechanisms deserve further investigation. This review first summarizes the effects of key regulatory factors of engineered biomaterials (including bioactive molecules, conductivity, and some microenvironmental factors) on macrophage behavior, then explores specific methods for inducing macrophage behavior through tissue engineering materials to promote myocardial repair, and summarizes the role of macrophage-host cell crosstalk in regulating inflammation, vascularization, and tissue remodeling. Finally, we propose some future challenges in regulating macrophage-material interactions and tailoring personalized biomaterials to guide macrophage phenotypes.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Tissue Engineering and Regenerative Medicine · Cardiac Fibrosis and Remodeling · Signaling Pathways in Disease
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Central Laboratory, The Fifth Affiliated Hospital
Southern Medical University
Department of Neurology, The Fifth Affiliated Hospital
Department of Neurology
Foshan Hospital of Traditional Chinese Medicine
Department of Anatomy, School of Basic Medical Science
Funding
National Natural Science Foundation of China · Guangdong Medical Research Foundation
References (100+)
Show source-provided references
1. World Health Organization. Cardiovascular diseases (CVDs). https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (accessed 2023–10–15).
2. 10.2174/1570161111311999000310.2174/15701611113119990003 ↗
3. 10.1097/FJC.000000000000000310.1097/FJC.0000000000000003 ↗
4. 10.1093/eurheartj/ehab84210.1093/eurheartj/ehab842 ↗
5. 10.1038/s41392-020-00455-610.1038/s41392-020-00455-6 ↗
6. 10.1038/s41591-018-0064-010.1038/s41591-018-0064-0 ↗
7. 10.1016/j.immuni.2013.11.01910.1016/j.immuni.2013.11.019 ↗
8. 10.1016/j.yjmcc.2015.11.01510.1016/j.yjmcc.2015.11.015 ↗
9. 10.1038/nrcardio.2014.2810.1038/nrcardio.2014.28 ↗
10. 10.1161/CIRCRESAHA.116.30357710.1161/CIRCRESAHA.116.303577 ↗
11. 10.1093/cvr/cvs01810.1093/cvr/cvs018 ↗
12. 10.1007/s00018-019-03048-x10.1007/s00018-019-03048-x ↗
13. 10.1016/j.jtcvs.2020.07.12410.1016/j.jtcvs.2020.07.124 ↗
14. 10.1161/CIRCULATIONAHA.122.06349510.1161/CIRCULATIONAHA.122.063495 ↗
15. 10.1161/CIRCRESAHA.121.31800510.1161/CIRCRESAHA.121.318005 ↗
16. 10.1016/j.yjmcc.2021.05.00810.1016/j.yjmcc.2021.05.008 ↗
17. 10.1016/j.engmic.2023.10010110.1016/j.engmic.2023.100101 ↗
18. 10.3760/cma.j.cn112147-20230816-0008110.3760/cma.j.cn112147-20230816-00081 ↗
19. 10.1038/s41590-022-01146-w10.1038/s41590-022-01146-w ↗
20. 10.1016/j.biopha.2023.11504210.1016/j.biopha.2023.115042 ↗
21. 10.1002/adhm.20230411410.1002/adhm.202304114 ↗
22. 10.1002/adma.20241265110.1002/adma.202412651 ↗
23. 10.1016/j.apsb.2020.12.01410.1016/j.apsb.2020.12.014 ↗
24. 10.1016/j.immuni.2016.02.02410.1016/j.immuni.2016.02.024 ↗
25. 10.1126/science.121917910.1126/science.1219179 ↗
26. 10.1016/j.immuni.2014.06.01310.1016/j.immuni.2014.06.013 ↗
27. 10.1161/ATVBAHA.116.30819810.1161/ATVBAHA.116.308198 ↗
28. 10.1021/acs.biochem.7b0012910.1021/acs.biochem.7b00129 ↗
29. 10.1161/CIRCRESAHA.118.31435710.1161/CIRCRESAHA.118.314357 ↗
30. 10.1177/1535370222108013010.1177/15353702221080130 ↗
31. 10.1016/j.jconrel.2016.01.02610.1016/j.jconrel.2016.01.026 ↗
32. 10.1039/C9TB02932J10.1039/C9TB02932J ↗
33. 10.1016/j.biomaterials.2013.02.06510.1016/j.biomaterials.2013.02.065 ↗
34. 10.1002/adhm.20180067510.1002/adhm.201800675 ↗
35. 10.1172/JCI5964310.1172/JCI59643 ↗
36. 10.1016/j.cytogfr.2011.10.00110.1016/j.cytogfr.2011.10.001 ↗
37. 10.1016/j.jhep.2016.02.00410.1016/j.jhep.2016.02.004 ↗
38. 10.1038/s41573-024-01053-910.1038/s41573-024-01053-9 ↗
39. 10.1164/rccm.202110-2274OC10.1164/rccm.202110-2274OC ↗
40. 10.1038/nri271110.1038/nri2711 ↗
41. 10.1038/s41392-024-01764-w10.1038/s41392-024-01764-w ↗
42. 10.1016/j.it.2004.09.01510.1016/j.it.2004.09.015 ↗
43. 10.3389/fimmu.2022.90167210.3389/fimmu.2022.901672 ↗
44. 10.4049/jimmunol.164.12.616610.4049/jimmunol.164.12.6166 ↗
45. 10.1038/s41598-020-67396-610.1038/s41598-020-67396-6 ↗
46. 10.3389/fimmu.2023.111172910.3389/fimmu.2023.1111729 ↗
47. 10.1038/s41467-023-43283-210.1038/s41467-023-43283-2 ↗
48. 10.1038/s41423-022-00841-w10.1038/s41423-022-00841-w ↗
49. 10.1111/imr.1221810.1111/imr.12218 ↗
50. 10.4049/jimmunol.179.8.536710.4049/jimmunol.179.8.5367 ↗
51. 10.1002/smll.20210411210.1002/smll.202104112 ↗
52. 10.1186/s12943-023-01827-610.1186/s12943-023-01827-6 ↗
53. 10.3109/10799893.2015.103041210.3109/10799893.2015.1030412 ↗
54. 10.3390/ijms2303146410.3390/ijms23031464 ↗
55. 10.1186/s13045-017-0471-610.1186/s13045-017-0471-6 ↗
56. 10.1681/ASN.201704039110.1681/ASN.2017040391 ↗
57. 10.1016/j.immuni.2024.08.01610.1016/j.immuni.2024.08.016 ↗
58. 10.1093/femsre/fuw00710.1093/femsre/fuw007 ↗
59. 10.1096/fj.201900799RR10.1096/fj.201900799RR ↗
60. 10.1038/ni.236610.1038/ni.2366 ↗
61. 10.1111/bph.1564210.1111/bph.15642 ↗
62. 10.1016/j.ebiom.2020.10303910.1016/j.ebiom.2020.103039 ↗
63. 10.1016/j.apsb.2023.05.03210.1016/j.apsb.2023.05.032 ↗
64. 10.1093/cvr/cvab00810.1093/cvr/cvab008 ↗
65. 10.1016/j.semcancer.2017.04.01210.1016/j.semcancer.2017.04.012 ↗
66. 10.1016/j.bbapap.2007.08.01210.1016/j.bbapap.2007.08.012 ↗
67. 10.1126/science.107268210.1126/science.1072682 ↗
68. 10.1016/j.molimm.2005.07.00610.1016/j.molimm.2005.07.006 ↗
69. 10.1042/BST2022027110.1042/BST20220271 ↗
70. 10.1074/jbc.C50035320010.1074/jbc.C500353200 ↗
71. 10.1016/j.gene.2022.14628410.1016/j.gene.2022.146284 ↗
72. 10.1038/sj.onc.120344310.1038/sj.onc.1203443 ↗
73. 10.1016/j.biomaterials.2023.12224710.1016/j.biomaterials.2023.122247 ↗
74. 10.4049/jimmunol.173.1.36010.4049/jimmunol.173.1.360 ↗
75. 10.1016/j.pharmthera.2003.08.00310.1016/j.pharmthera.2003.08.003 ↗
76. 10.1016/j.blre.2020.10069410.1016/j.blre.2020.100694 ↗
77. 10.1038/ni.320510.1038/ni.3205 ↗
78. 10.1016/j.immuni.2009.09.00210.1016/j.immuni.2009.09.002 ↗
79. 10.1038/ni.289110.1038/ni.2891 ↗
80. 10.1016/j.cmet.2016.10.01810.1016/j.cmet.2016.10.018 ↗
81. 10.1038/s41467-019-11147-310.1038/s41467-019-11147-3 ↗
82. 10.1038/s41577-018-0029-z10.1038/s41577-018-0029-z ↗
83. 10.1016/j.cytogfr.2016.03.01010.1016/j.cytogfr.2016.03.010 ↗
84. 10.1002/mco2.29310.1002/mco2.293 ↗
85. 10.1093/carcin/bgr24210.1093/carcin/bgr242 ↗
86. 10.1161/CIRCULATIONAHA.121.05754910.1161/CIRCULATIONAHA.121.057549 ↗
87. 10.1084/jem.176.1.28710.1084/jem.176.1.287 ↗
88. 10.1111/j.1365-2567.2004.01988.x10.1111/j.1365-2567.2004.01988.x ↗
89. 10.1046/j.1365-2567.1997.00371.x10.1046/j.1365-2567.1997.00371.x ↗
90. 10.1016/j.intimp.2024.11155710.1016/j.intimp.2024.111557 ↗
91. 10.1111/all.1415110.1111/all.14151 ↗
92. 10.1182/blood.V95.2.49410.1182/blood.V95.2.494 ↗
93. 10.1038/nri308810.1038/nri3088 ↗
94. 10.1016/j.celrep.2023.11247110.1016/j.celrep.2023.112471 ↗
95. 10.1016/j.gendis.2023.02.03910.1016/j.gendis.2023.02.039 ↗
96. 10.1093/intimm/dxu09010.1093/intimm/dxu090 ↗
97. 10.1016/j.autrev.2020.10261710.1016/j.autrev.2020.102617 ↗
98. 10.1155/2010/67436310.1155/2010/674363 ↗
99. 10.1002/JLB.3RU1018-378RR10.1002/JLB.3RU1018-378RR ↗
100. 10.1038/nrrheum.2010.410.1038/nrrheum.2010.4 ↗